Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy
Maureen G. Maguire, Danni Liu, Susan B. Bressler, Scott M. Friedman et autres
IMPORTANCE: The follow-up schedule for individuals with eyes treated with anti-vascular endothelial growth factor agents for proliferative diabetic retinopathy (PDR) requires that patients return frequently for monitoring and repeated treatment. The likelihood that a patient will comply should be a consideration in …
us (code pays fourni par la source)